Compounders Research Compare

CVRx, Inc.(CVRX)

Medical - Devices · Minneapolis, MN

$1.67+0.11 (+7.15%)

Delayed quote: Oct 6, 2026, 11:50 AM EDT

About CVRx, Inc.

CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.

Minneapolis, MN

223 employees

www.barostim.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Kevin Hykes

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T15:51:09.009Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:51:09.009Z.

Quote observation: 2026-10-06T15:50:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 44,357,484
Total debt · period ending 2026-06-30: 59,390,000
Cash · period ending 2026-06-30: 64,586,000
TTM free cash flow · period ending 2026-06-30: -41,054,000

FMP input reference: e78bbdb3a8988fdd9fdd63a4dcf124b38851ed281a9b1f93071349952e7e00d5

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CVRX EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

CVRX Competitors' EV/FCF Ratio

CVRx, Inc.

Current

Market Cap

$44.36M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Nano-X Imaging Ltd.

Market Cap

$44.20M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BioStem Technologies, Inc.

Market Cap

$44.11M

EV/FCF Ratio

N/A

TTM Avg

16.14x

3Y Avg

18.58x

5Y Avg

128.19x

Werewolf Therapeutics, Inc.

Market Cap

$45.22M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DarioHealth Corp.

Market Cap

$44.35M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Precipio, Inc.

Market Cap

$41.92M

EV/FCF Ratio

53.46x

TTM Avg

75.69x

3Y Avg

62.69x

5Y Avg

62.69x

Filana Therapeutics, Inc.

Market Cap

$41.65M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Precision Optics Corporation, Inc.

Market Cap

$48.05M

EV/FCF Ratio

N/A

TTM Avg

104.90x

3Y Avg

104.90x

5Y Avg

95.87x

Metagenomi, Inc. Common Stock

Market Cap

$40.28M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Nephros, Inc.

Market Cap

$40.06M

EV/FCF Ratio

N/A

TTM Avg

32.59x

3Y Avg

41.40x

5Y Avg

41.40x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
CVRx, Inc. (CVRX)	$44.36M	N/A	N/A	N/A	N/A
Nano-X Imaging Ltd. (NNOX)vs ›	$44.20M	N/A	N/A	N/A	N/A
BioStem Technologies, Inc. (BSEM)vs ›	$44.11M	N/A	16.14x	18.58x	128.19x
Werewolf Therapeutics, Inc. (HOWL)vs ›	$45.22M	N/A	N/A	N/A	N/A
DarioHealth Corp. (DRIO)vs ›	$44.35M	N/A	N/A	N/A	N/A
Precipio, Inc. (PRPO)vs ›	$41.92M	53.46x	75.69x	62.69x	62.69x
Filana Therapeutics, Inc. (FLNA)vs ›	$41.65M	N/A	N/A	N/A	N/A
Precision Optics Corporation, Inc. (POCI)vs ›	$48.05M	N/A	104.90x	104.90x	95.87x
Metagenomi, Inc. Common Stock (MGX)vs ›	$40.28M	N/A	N/A	N/A	N/A
Nephros, Inc. (NEPH)vs ›	$40.06M	N/A	32.59x	41.40x	41.40x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics